Literature DB >> 25792355

Frequency and prognostic impact of casein kinase 1A1 mutations in MDS patients with deletion of chromosome 5q.

M Heuser1, M Meggendorfer2, M M A Cruz1, J Fabisch1, S Klesse1, L Köhler1, G Göhring3, C Ganster4, K Shirneshan4, A Gutermuth4, S Cerny-Reiterer5, J Krönke6, V Panagiota1, C Haferlach2, C Koenecke1, U Platzbecker7, C Thiede7, T Schroeder8, G Kobbe8, S Ehrlich1, K Stamer1, K Döhner6, P Valent5, B Schlegelberger3, N Kroeger9, A Ganser1, D Haase4, T Haferlach2, F Thol2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25792355     DOI： 10.1038/leu.2015.49

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  13 in total

1.  TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression.

Authors:  Martin Jädersten; Leonie Saft; Alexander Smith; Austin Kulasekararaj; Sabine Pomplun; Gudrun Göhring; Anette Hedlund; Robert Hast; Brigitte Schlegelberger; Anna Porwit; Eva Hellström-Lindberg; Ghulam J Mufti
Journal:  J Clin Oncol       Date:  2011-04-25       Impact factor: 44.544

2.  Genome-wide analysis of copy number changes and loss of heterozygosity in myelodysplastic syndrome with del(5q) using high-density single nucleotide polymorphism arrays.

Authors:  Li Wang; Carrie Fidler; Nandita Nadig; Aristoteles Giagounidis; Matteo G Della Porta; Luca Malcovati; Sally Killick; Norbert Gattermann; Carlo Aul; Jacqueline Boultwood; James S Wainscoat
Journal:  Haematologica       Date:  2008-05-27       Impact factor: 9.941

3.  SETBP1 mutation analysis in 944 patients with MDS and AML.

Authors:  F Thol; K J Suchanek; C Koenecke; M Stadler; U Platzbecker; C Thiede; T Schroeder; G Kobbe; S Kade; P Löffeld; S Banihosseini; G Bug; O Ottmann; W-K Hofmann; J Krauter; N Kröger; A Ganser; M Heuser
Journal:  Leukemia       Date:  2013-05-07       Impact factor: 11.528

4.  Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes.

Authors:  Felicitas Thol; Inna Friesen; Frederik Damm; Haiyang Yun; Eva M Weissinger; Jürgen Krauter; Katharina Wagner; Anuhar Chaturvedi; Amit Sharma; Martin Wichmann; Gudrun Göhring; Christiane Schumann; Gesine Bug; Oliver Ottmann; Wolf-Karsten Hofmann; Brigitte Schlegelberger; Michael Heuser; Arnold Ganser
Journal:  J Clin Oncol       Date:  2011-05-16       Impact factor: 44.544

5.  Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype.

Authors:  Daniel T Starczynowski; Florian Kuchenbauer; Bob Argiropoulos; Sandy Sung; Ryan Morin; Andrew Muranyi; Martin Hirst; Donna Hogge; Marco Marra; Richard A Wells; Rena Buckstein; Wan Lam; R Keith Humphries; Aly Karsan
Journal:  Nat Med       Date:  2009-11-08       Impact factor: 53.440

6.  Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS.

Authors:  Rebekka K Schneider; Vera Ademà; Dirk Heckl; Marcus Järås; Mar Mallo; Allegra M Lord; Lisa P Chu; Marie E McConkey; Rafael Kramann; Ann Mullally; Rafael Bejar; Francesc Solé; Benjamin L Ebert
Journal:  Cancer Cell       Date:  2014-09-18       Impact factor: 31.743

7.  Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes.

Authors:  Timothy A Graubert; Dong Shen; Li Ding; Theresa Okeyo-Owuor; Cara L Lunn; Jin Shao; Kilannin Krysiak; Christopher C Harris; Daniel C Koboldt; David E Larson; Michael D McLellan; David J Dooling; Rachel M Abbott; Robert S Fulton; Heather Schmidt; Joelle Kalicki-Veizer; Michelle O'Laughlin; Marcus Grillot; Jack Baty; Sharon Heath; John L Frater; Talat Nasim; Daniel C Link; Michael H Tomasson; Peter Westervelt; John F DiPersio; Elaine R Mardis; Timothy J Ley; Richard K Wilson; Matthew J Walter
Journal:  Nat Genet       Date:  2011-12-11       Impact factor: 38.330

8.  Csnk1a1 inhibition has p53-dependent therapeutic efficacy in acute myeloid leukemia.

Authors:  Marcus Järås; Peter G Miller; Lisa P Chu; Rishi V Puram; Emma C Fink; Rebekka K Schneider; Fatima Al-Shahrour; Pablo Peña; L Jordan Breyfogle; Kimberly A Hartwell; Marie E McConkey; Glenn S Cowley; David E Root; Michael G Kharas; Ann Mullally; Benjamin L Ebert
Journal:  J Exp Med       Date:  2014-03-10       Impact factor: 14.307

9.  Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS.

Authors:  A F List; J M Bennett; M A Sekeres; B Skikne; T Fu; J M Shammo; S D Nimer; R D Knight; A Giagounidis
Journal:  Leukemia       Date:  2013-10-22       Impact factor: 11.528

10.  Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo.

Authors:  Petter S Woll; Una Kjällquist; Onima Chowdhury; Helen Doolittle; David C Wedge; Supat Thongjuea; Rikard Erlandsson; Mtakai Ngara; Kristina Anderson; Qiaolin Deng; Adam J Mead; Laura Stenson; Alice Giustacchini; Sara Duarte; Eleni Giannoulatou; Stephen Taylor; Mohsen Karimi; Christian Scharenberg; Teresa Mortera-Blanco; Iain C Macaulay; Sally-Ann Clark; Ingunn Dybedal; Dag Josefsen; Pierre Fenaux; Peter Hokland; Mette S Holm; Mario Cazzola; Luca Malcovati; Sudhir Tauro; David Bowen; Jacqueline Boultwood; Andrea Pellagatti; John E Pimanda; Ashwin Unnikrishnan; Paresh Vyas; Gudrun Göhring; Brigitte Schlegelberger; Magnus Tobiasson; Gunnar Kvalheim; Stefan N Constantinescu; Claus Nerlov; Lars Nilsson; Peter J Campbell; Rickard Sandberg; Elli Papaemmanuil; Eva Hellström-Lindberg; Sten Linnarsson; Sten Eirik W Jacobsen
Journal:  Cancer Cell       Date:  2014-05-15       Impact factor: 31.743
View more
  8 in total

Review 1.  Treatments targeting MDS genetics: a fool's errand?

Authors:  Amy E DeZern
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

2.  Pathophysiologic and clinical implications of molecular profiles resultant from deletion 5q.

Authors:  Vera Adema; Laura Palomo; Wencke Walter; Mar Mallo; Stephan Hutter; Thomas La Framboise; Leonor Arenillas; Manja Meggendorfer; Tomas Radivoyevitch; Blanca Xicoy; Andrea Pellagatti; Claudia Haferlach; Jacqueline Boultwood; Wolfgang Kern; Valeria Visconte; Mikkael Sekeres; John Barnard; Torsten Haferlach; Francesc Solé; Jaroslaw P Maciejewski
Journal:  EBioMedicine       Date:  2022-05-23       Impact factor: 11.205

3.  Distinct splicing signatures affect converged pathways in myelodysplastic syndrome patients carrying mutations in different splicing regulators.

Authors:  Jinsong Qiu; Bing Zhou; Felicitas Thol; Yu Zhou; Liang Chen; Changwei Shao; Christopher DeBoever; Jiayi Hou; Hairi Li; Anuhar Chaturvedi; Arnold Ganser; Rafael Bejar; Dong-Er Zhang; Xiang-Dong Fu; Michael Heuser
Journal:  RNA       Date:  2016-08-04       Impact factor: 4.942

4.  Hypermethylation of the VTRNA1-3 Promoter is Associated with Poor Outcome in Lower Risk Myelodysplastic Syndrome Patients.

Authors:  Alexandra Søgaard Helbo; Marianne Treppendahl; Derya Aslan; Konstantinos Dimopoulos; Cecilie Nandrup-Bus; Mette Skov Holm; Mette Klarskov Andersen; Gangning Liang; Lasse Sommer Kristensen; Kirsten Grønbæk
Journal:  Genes (Basel)       Date:  2015-10-14       Impact factor: 4.096

5.  Molecular analysis of myelodysplastic syndrome with isolated deletion of the long arm of chromosome 5 reveals a specific spectrum of molecular mutations with prognostic impact: a study on 123 patients and 27 genes.

Authors:  Manja Meggendorfer; Claudia Haferlach; Wolfgang Kern; Torsten Haferlach
Journal:  Haematologica       Date:  2017-06-22       Impact factor: 9.941

6.  Clonal evolution in myelodysplastic syndromes.

Authors:  Pedro da Silva-Coelho; Leonie I Kroeze; Kenichi Yoshida; Theresia N Koorenhof-Scheele; Ruth Knops; Louis T van de Locht; Aniek O de Graaf; Marion Massop; Sarah Sandmann; Martin Dugas; Marian J Stevens-Kroef; Jaroslav Cermak; Yuichi Shiraishi; Kenichi Chiba; Hiroko Tanaka; Satoru Miyano; Theo de Witte; Nicole M A Blijlevens; Petra Muus; Gerwin Huls; Bert A van der Reijden; Seishi Ogawa; Joop H Jansen
Journal:  Nat Commun       Date:  2017-04-21       Impact factor: 14.919

7.  Recurrent genetic defects on chromosome 5q in myeloid neoplasms.

Authors:  Naoko Hosono; Hideki Makishima; Reda Mahfouz; Bartlomiej Przychodzen; Kenichi Yoshida; Andres Jerez; Thomas LaFramboise; Chantana Polprasert; Michael J Clemente; Yuichi Shiraishi; Kenichi Chiba; Hiroko Tanaka; Satoru Miyano; Masashi Sanada; Edward Cui; Amit K Verma; Michael A McDevitt; Alan F List; Yogen Saunthararajah; Mikkael A Sekeres; Jacqueline Boultwood; Seishi Ogawa; Jaroslaw P Maciejewski
Journal:  Oncotarget       Date:  2017-01-24

8.  Genetic barcoding systematically compares genes in del(5q) MDS and reveals a central role for CSNK1A1 in clonal expansion.

Authors:  Ursula S A Stalmann; Fabio Ticconi; Inge A M Snoeren; Ronghui Li; Hélène F E Gleitz; Glenn S Cowley; Marie E McConkey; Aaron B Wong; Stephani Schmitz; Stijn N R Fuchs; Shubhankar Sood; Nils B Leimkühler; Sergio Martinez-Høyer; Bella Banjanin; David Root; Tim H Brümmendorf; Juliette E Pearce; Andreas Schuppert; Eric M J Bindels; Marieke A Essers; Dirk Heckl; Thomas Stiehl; Ivan G Costa; Benjamin L Ebert; Rebekka K Schneider
Journal:  Blood Adv       Date:  2022-03-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.